TY - GEN
T1 - Alpha-glucosidase inhibitory activity of stingless bee honey from Tetragonula biroi and Tetragonula laeviceps
AU - Rahmawati, Oktavia
AU - Pratami, Diah Kartika
AU - Raffiudin, Rika
AU - Sahlan, Muhamad
PY - 2019/4/9
Y1 - 2019/4/9
N2 -
Diabetes Mellitus (DM) is a metabolic disease characterized by chronic hyperglycemia in the presence of carbohydrate, fat, and protein metabolism disorder. Diabetes mellitus can be treated by inhibiting the activity of the alpha-glucosidase enzyme that serves to break down carbohydrates into glucose. Honey is known to have many health benefits. This study aims to determine the alpha-glucosidase enzyme inhibitory activity of stingless bee honey from Tetragonula biroi and Tetragonula laeviceps. Stingless bee honey from T. biroi and T. laeviceps with various concentrations (50-1000ppm) were tested to obtain the IC
50
value. Acarbose was used as a positive control. This study was performed by measuring the absorbance of the reaction mixture (phosphate buffer, 4-nitrophenyl α-D-glucopyranoside, α-glucosidase, and sample) using a microplate reader at 410nm. The results obtained that stingless bee honey from T. biroi and T. laeviceps has a potency to inhibit the activity of the α-glucosidase enzyme. However, the methanol extract of T. laeviceps honey has the highest ability to inhibit the activity of the α-glucosidase enzyme with IC
50
values of around 2394.69ppm. Therefore, some animal testing or more research were needed to investigate the potential of stingless bee honey from T. biroi and T. laeviceps for diabetic treatment.
AB -
Diabetes Mellitus (DM) is a metabolic disease characterized by chronic hyperglycemia in the presence of carbohydrate, fat, and protein metabolism disorder. Diabetes mellitus can be treated by inhibiting the activity of the alpha-glucosidase enzyme that serves to break down carbohydrates into glucose. Honey is known to have many health benefits. This study aims to determine the alpha-glucosidase enzyme inhibitory activity of stingless bee honey from Tetragonula biroi and Tetragonula laeviceps. Stingless bee honey from T. biroi and T. laeviceps with various concentrations (50-1000ppm) were tested to obtain the IC
50
value. Acarbose was used as a positive control. This study was performed by measuring the absorbance of the reaction mixture (phosphate buffer, 4-nitrophenyl α-D-glucopyranoside, α-glucosidase, and sample) using a microplate reader at 410nm. The results obtained that stingless bee honey from T. biroi and T. laeviceps has a potency to inhibit the activity of the α-glucosidase enzyme. However, the methanol extract of T. laeviceps honey has the highest ability to inhibit the activity of the α-glucosidase enzyme with IC
50
values of around 2394.69ppm. Therefore, some animal testing or more research were needed to investigate the potential of stingless bee honey from T. biroi and T. laeviceps for diabetic treatment.
KW - Alpha-glucosidase
KW - diabetes mellitus
KW - stingless bee honey
KW - Tetragonula biroi
KW - Tetragonula laeviceps
UR - http://www.scopus.com/inward/record.url?scp=85064817157&partnerID=8YFLogxK
U2 - 10.1063/1.5096705
DO - 10.1063/1.5096705
M3 - Conference contribution
AN - SCOPUS:85064817157
T3 - AIP Conference Proceedings
BT - 3rd Biomedical Engineering''s Recent Progress in Biomaterials, Drugs Development, and Medical Devices
A2 - Wulan, Praswasti P.D.K.
A2 - Gozan, Misri
A2 - Astutiningsih, Sotya
A2 - Ramahdita, Ghiska
A2 - Dhelika, Radon
A2 - Kreshanti, Prasetyanugraheni
PB - American Institute of Physics Inc.
T2 - 3rd International Symposium of Biomedical Engineering''s Recent Progress in Biomaterials, Drugs Development, and Medical Devices, ISBE 2018
Y2 - 6 August 2018 through 8 August 2018
ER -